Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/075—Ethers or acetals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/075—Ethers or acetals
  • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
  • A61K36/484—Glycyrrhiza (licorice)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
  • A61K8/345—Alcohols containing more than one hydroxy group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/35—Ketones, e.g. benzophenone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9789—Magnoliopsida [dicotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/005—Preparations for sensitive skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/007—Preparations for dry skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• the present invention relates to cosmetic or dermatological preparations containing active substances for the care and protection of the skin, in particular sensitive skin, as well as skin aged or aging through intrinsic and/or extrinsic factors and the use of such active substances and combinations of such substances in the field of cosmetic and dermatological skin care.
• Cosmetic skin care is primarily understood as meaning that the natural function of the skin as a barrier against environmental influences (e.g. dirt, chemicals, micro-organisms) and against the loss of substances intrinsic to the body (e.g. water, natural fats, electrolytes) is strengthened or restored. Impairment of this function may lead to increased absorption of toxic or allergenic substances or to attack by microorganisms, resulting in toxic or allergic skin reactions.
• environmental influences e.g. dirt, chemicals, micro-organisms
• substances intrinsic to the body e.g. water, natural fats, electrolytes
• the barrier effect of the skin can be quantified by determining the transepidermal water loss (TEWL).
• TEWL transepidermal water loss
• This process involves the evaporation of water from the interior of the body without including the loss of water during perspiration.
• the determination of the TEWL value has proven to be extremely informative, and may be used for diagnosing cracked or chapped skin, for determining the compatibility of chemically differently composed surfactants and the like.
• the proportion of water in the uppermost skin layer is of greatest importance. It is possible to influence the proportion of water favorably and to a limited extent by introducing moisture regulators.
• Anionic surfactants which are in general ingredients of cleansing preparations, are capable of increasing the pH value in the horny layer in a long-lasting manner, which greatly impedes regenerative processes that serve to restore or renew the barrier function of the skin.
• a new, often very unfavorable state of equilibrium develops in the horny layer between regeneration and loss of essential substances as a result of regular extraction. This state of equilibrium decisively affects the outer appearance of the skin and the physiological functioning of the horny layer.
• a simple water bath alone without the addition of surfactants causes an initial swelling of the horny layer of the skin, with the degree of this swelling being dependent, e.g., on the duration of the bath and its temperature.
• water-soluble substances for example, water-soluble dirt particles
• skin-inherent substances which are responsible for the capacity of the horny layer to bind water
• skin-inherent, surface-active substances also cause skin fats to be separated and washed away to a certain extent. After an initial swelling, this causes a subsequent, distinct drying of the skin, which may be increased further by detergent additives.
• lipid composition and lipid quantity of the horny layer of the pathologically altered, dry skin and of the dry but not yet diseased skin of younger and older people deviate from the normal condition which is found in the healthy, normally hydrated skin of a same age group.
• changes in the lipid pattern of the very dry, non-eczematous skin of patients with an atopic eczema represent an extreme case of the deviations which are found in the dry skin of people with healthy skin.
• ceramides which are greatly reduced in their quantity and, in addition, differently composed.
• the deficit of ceramides 1 and 3 is particularly striking, it being known in particular in the case of ceramide 1 that it increases in a special way the order of the lipids in the intercellular membrane systems.
• the effect of ointments and creams on the barrier function and hydration of the horny layer does not normally comprise a restoration or strengthening of the physico-chemical properties of the lamellae from intercellular lipids.
• a substantial partial effect is based on the mere covering of the treated skin regions and on the resultant water collection in the subjacent horny layer.
• Co-applied hygroscopic substances bind the water, so that a measurable increase of the water content in the horny layer develops.
• Skin care as intended by the present invention includes primarily that the natural function of the skin as a barrier against environmental influences (for example, dirt, chemicals, microorganisms) and against the loss of endogenous substances (for example, water, lipids, electrolytes) is strengthened or restored.
• environmental influences for example, dirt, chemicals, microorganisms
• endogenous substances for example, water, lipids, electrolytes
• Products for the care, treatment, and cleansing of dry and stressed skin are known per se. However, their contribution to the regeneration of a physiologically intact, hydrated and smooth horny layer is limited in terms of scope and time.
• the action of ointments and creams on the barrier function and the hydration of the horny layer is based substantially on the coverage (occlusion) of the treated skin regions.
• the ointment or cream represents as it were a (second) artificial barrier, which is intended to prevent a loss of water by the skin. Accordingly, this physical barrier is again easy to remove—for example, with cleansing agents—so that the original, impaired condition is reestablished. Moreover, the effect of the skin care may subside in the case of a regular treatment. After the product application is discontinued, the skin returns again very quickly to its condition before the start of the treatment. In the case of certain products, the condition of the skin sometimes even deteriorates temporarily. Thus, a long-lasting effect of the product is not achieved, or only achieved to a limited extent.
• the effect of some pharmaceutical preparations on the barrier function of the skin even comprises a selective barrier damage, which is intended to make it possible for active substances to penetrate into the skin or through the skin into the body.
• a selective barrier damage which is intended to make it possible for active substances to penetrate into the skin or through the skin into the body.
• an impaired appearance of the skin as a side effect is partially accepted.
• the effect of skin care cleansing products comprises in essence an efficient regreasing with sebum lipid-like substances.
• preparations for skin care and preparations for cleansing the skin which maintain or restore the barrier properties of the skin, particularly when the natural regeneration of the skin is insufficient.
• these preparations should be suitable for the treatment and prophylaxis of secondary damage from the drying out of the skin, for example, fissures or inflammatory or allergic processes, or even neurodermatitis.
• available stable, skin care cosmetic and/or dermatological agents which protect the skin against environmental influences, such as sun and wind. In particular, it is desired that the effect of the preparation be physiological, fast, and long-lasting.
• the present invention furthermore relates to preparations with extremely low so-called “stinging potential.”
• This “sensitive skin” differs in principle from “dry skin” with thickened and hardened horny layers.
• Typical reactions of “stinging” on sensitive skin are reddening, tightening and burning of the skin and itching.
• “Stinging” phenomena can be regarded as disturbances that can be treated cosmetically. Severe itching, on the other hand, especially severe itching of the skin which occurs with atopy, can also be described as a more serious dermatological disorder.
• Typical troublesome neurosensory phenomena associated with the terms “stinging” or “sensitive skin” are reddening of the skin, tingling, prickling, tightening and burning of the skin and itching. These phenomena can be caused by stimulating environmental conditions, for example massage, action of surfactants, the influence of weather, such as sun, cold, dryness, and also damp heat, radiant heat and UV radiation, for example from the sun.
• Sensitive skin describes a combination of different symptoms, such as hyperreactive and intolerant skin. Atopic skin can also be included under this term. These skin conditions are often referred to by those affected, not quite correctly, as “allergic” skin. Although an allergic disorder can result in symptoms of sensitive skin, the “sensitive skin” phenomenon is not limited to allergy sufferers.
• Erythematous skin symptoms also occur as concomitant symptoms with certain skin diseases or irregularities.
• the typical skin rash with the clinical picture of acne, for example, is regularly reddened to a greater or lesser degree.
• the present invention relates, inter alia, to cosmetic and dermatological preparations for the prophylaxis and treatment of cosmetic or dermatological skin alterations, such as, e.g., undesirable pigmentation, e.g., local hyperpigmentation and abnormal pigmentation (e.g., moles, freckles), but also for the purely cosmetic lightening of larger skin areas that are per se appropriately pigmented for the individual skin type.
• cosmetic or dermatological skin alterations such as, e.g., undesirable pigmentation, e.g., local hyperpigmentation and abnormal pigmentation (e.g., moles, freckles)
• undesirable pigmentation e.g., local hyperpigmentation and abnormal pigmentation (e.g., moles, freckles)
• abnormal pigmentation e.g., moles, freckles
• Pigmentation of the skin is due to melanocytes, which are found in the bottom layer of the epidermis, the basal stratum, next to the basal cells, which—depending on skin type—are present as pigment-forming cells either individually or in relatively large numbers.
• Melanocytes contain melanosomes as characteristic cell organelles, which produce more melanin when stimulated by UV radiation. The melanin is transported into the keratinocytes and causes more or less pronounced brownish or brown skin coloring.
• Melanin is formed as the final stage in an oxidation process, in which tyrosine, with the aid of the enzyme tyrosinase, is converted to melanin via 3,4-dihydroxyphenyl alanine (dopa), dopa-quinone, leucodopachrome, dopachrome, 5,6-dihydroxyindol and indole-5,6-quinone.
• dopa 3,4-dihydroxyphenyl alanine
• dopa-quinone dopa-quinone
• leucodopachrome dopachrome
• dopachrome 5,6-dihydroxyindol and indole-5,6-quinone.
• UV radiation e.g. freckles, ephelides
• genetic disposition e.g., defective pigmentation of the skin and/or scarring during the healing of wounds, or skin aging (e.g. lentigines seniles ).
• Another goal of skin care is to compensate for the loss by the skin of sebum and water caused by daily washing. This is particularly important if the natural regeneration ability is inadequate. Furthermore, skin care products should protect against environmental influences, in particular against sun and wind, and delay skin aging.
• Chronological skin aging is caused, for example, by endogenous, genetically determined factors.
• Exogenous factors such as UV light and chemical noxae, can have a cumulative effect and, for example, accelerate or supplement the endogenous aging processes.
• the following structural damage and functional disorders appear in the skin as a result of exogenous factors; these go beyond the extent and quality of the damage in the case of chronological aging:
• the present invention also relates to products for the care of naturally aged skin, and to the treatment of the damage caused by photoaging, in particular of the phenomena listed under a) through g).
• Products for the care of aged skin are known per se. They contain, for example, niacinamide, retinoids (vitamin A acid and/or derivatives thereof) or vitamin A and/or derivatives thereof.
• retinoids vitamin A acid and/or derivatives thereof
• the extent of their effect on structural damage is, however, limited.
• product development there are considerable difficulties in stabilizing the active ingredients to an adequate extent against oxidative decay.
• the use of products comprising vitamin A acid moreover, often causes severe erythematous skin irritations. Retinoids can therefore only be used in low concentrations.
• the present invention also relates to cosmetic preparations which provide effective protection against harmful oxidation processes in the skin, and also for the protection of cosmetic preparations themselves or the protection of the constituents of cosmetic preparations against harmful oxidation processes.
• the present invention further relates to antioxidants, preferably those used in cosmetic or dermatological skin care preparations.
• the present invention also relates to cosmetic and dermatological preparations that comprise such antioxidants.
• the present invention relates to cosmetic and dermatological preparations for the prophylaxis and treatment of cosmetic and dermatological skin changes, such as, for example, skin aging, in particular skin aging caused by oxidative processes.
• the present invention relates to active substances and preparations comprising such active substances for the cosmetic and dermatological treatment or prophylaxis of erythematous, inflammatory, allergic or autoimmune-reactive symptoms, in particular dermatoses.
• the present invention relates to active ingredient combinations and preparations which serve for the prophylaxis and treatment of light-sensitive skin, in particular of photodermatoses.
• UVC range rays with a wavelength of less than about 290 nm
• UVB range rays in the range between about 290 nm and about 320 nm
• a maximum erythema activity of sunlight is indicated to occur within the relatively narrow range around 308 nm.
• UVA radiation results in damage of the elastic and collagenous fibers of connective tissue, which leads to premature aging of the skin, and is to be regarded as a cause of numerous phototoxic and photoallergic reactions.
• the harmful effect of UVB radiation can be intensified by UVA radiation.
• UV radiation can, however, also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin metabolism.
• Such photochemical reaction products are predominantly free radical compounds, for example hydroxyl radicals and singlet oxygen.
• Undefined free radical photoproducts which form in the skin itself can also display uncontrolled secondary reactions because of their high reactivity.
• singlet oxygen a non-free radical excited state of the oxygen molecule, can also be formed during UV irradiation, as can short-lived epoxides and many others.
• Singlet oxygen for example, differs from normal triplet oxygen (free radical ground state) by virtue of its increased reactivity.
• excited, reactive (free radical) triplet states of the oxygen molecule also exist.
• UV radiation is also a type of ionizing radiation. There is therefore the risk that ionic species will also form during UV exposure, which for their part are able to interfere oxidatively with the biochemical processes.
• antioxidants and/or free radical scavengers can be incorporated into cosmetic or dermatological formulations.
• vitamin E a substance with known antioxidant action, in sunscreen formulations, although, here too, the effect achieved falls far short of expectations.
• Antioxidants are mainly used as substances which protect against the deterioration of the preparations in which they are present. Nevertheless, it is known that in human or animal skin undesired oxidation processes may occur as well. Such processes play an important role in skin aging.
• antioxidants and/or free radical scavengers can be additionally incorporated into cosmetic or dermatological formulations.
• licochalcone A The anti-inflammatory effect of licochalcone A is known per se. To obtain this effect in topical formulations, however, the solubility of licochalcone A in the vehicle and a sufficient dermal bioavailability are important prerequisites. However, licochalcone A is a poorly soluble substance which can crystallize during storage and processing. This crystallization tendency is a great problem, since substance crystals can lead to an uncosmetic appearance, formula instabilities and/or loss of effectiveness.
• the present invention provides an active substance combination comprising:
• the weight ratio (A:B:C) is a:b:c, where a, b and c independently of one another may represent rational numbers of from about 0.001 to about 200, e.g., rational numbers of up to about 10, and
• the weight ratio (B+C)/(A*100) may be from about 0.1 to about 5,000, e.g., from about 0.5 to about 1,000, or from about 1 to about 1,000.
• the present invention also provides a cosmetic or dermatological preparation which comprises an effective amount of the active substance of the present invention, including the various aspects thereof as set forth above.
• the preparation may comprise from about 0.0005% to about 50% by weight, e.g., from about 0.01% to about 20% by weight of the active substance combination, based on the total weight of the preparation.
• the preparation may comprise from about 0.0001% to about 5% by weight, e.g., from about 0.001% to about 1% by weight, or from about 0.005% to about 0.5% by weight of licochalcone A, based on the total weight of the preparation.
• the preparation may comprise from about 0.001% to about 5% by weight, e.g., from about 0.01% to about 2% by weight, or from about 0.1% to about 0.5% by weight of phenoxyethanol, based on the total weight of the preparation.
• the preparation may comprise from about 0.001% to about 30% by weight, e.g., from about 0.01% to about 15% by weight, or from about 1% to about 8% by weight of glycerin, based on the total weight of the preparation.
• the preparation may further comprise from about 0.001% to about 20% by weight, e.g., from about 0.01% to about 10% by weight, or from about 0.05% to about 5% by weight of one or more polyols, based on the total weight of the preparation.
• the present invention further provides a cosmetic or dermatological preparation which comprises from about 0.01% to about 20% by weight, based on the total weight of the preparation, of an active substance combination comprising:
• the weight ratio (A:B:C) is a:b:c, where a, b and c independently of one another may represent rational numbers of from about 0.001 to about 10, and
• the weight ratio (B+C)/(A*100) may be from about 0.1 to about 1,000.
• the preparation may comprise from about 0.001% to about 1% by weight, e.g., from about 0.005% to about 0.5% by weight of licochalcone A.
• the preparation may comprise from about 0.01% to about 2% by weight, e.g., from about 0.1% to about 0.5% by weight of phenoxyethanol, based on the total weight of the preparation.
• the preparation may comprise from about 0.001% to about 30% by weight, e.g., from about 0.01% to about 15% by weight, or from about 1% to about 8% by weight of glycerin, based on the total weight of the preparation.
• the preparation may further comprise from about 0.001% to about 20% by weight, e.g, from about 0.01% to about 10% by weight, or from about 0.05% to about 5% by weight of one or more polyols, based on the total weight of the preparation.
• the present invention also provides an emulsion which comprises the preparation of the present invention, including the various aspects thereof as set forth above.
• the present invention also provides a method for the prophylaxis or treatment of inflammatory skin conditions and a method for protecting dry and sensitive skin. These methods comprise applying to at least a part of the skin the preparation of the present invention, including the various aspects thereof as set forth above.
• active substance combinations according to the invention or cosmetic or topical dermatological preparations with an effective content of active substance combinations according to the invention surprisingly provides not only an effective treatment, but also a prophylaxis of
• licochalcone A which is characterized by the following structural formula:
• Phenoxyethanol is a viscous liquid with a light, slightly pleasant scent and an astringent taste. Phenoxyethanol is found in nature, inter alia, in tropical fruit, in cichorium endiva and in green tea ( camellia sinesis ). It has a mild, rose-like scent and is also used as a fixative for perfume compositions. It is miscible with acetone, ethyl alcohol and glycerin and is soluble in water and fats, e.g., olive oil and peanut oil.
• Phenoxyethanol is effective above all in acidic and neutral, as well as in an alkaline media and is completely non-toxic. It provides sufficient protection already in low concentrations. Due to its good tolerability together with its excellent effectiveness it was quickly adopted in the pharmaceutical and cosmetic industry.
• glycerin moisturizes and smoothes the skin and is a constituent of many skin care cosmetic preparations.
• the preparations of the present invention contains at least about 0.001%, e.g., at least about 0.01%, at least about 0.1%, or at least about 1% by weight, but preferably not more than about 30%, e.g., not more than about 15%, or not more than about 8% by weight of glycerin, based on the total weight of the preparation.
• a preparation according to the invention will contain at least about 0.001%, e.g., at least about 0.01%, or at least about 0.1 by weight, but preferably not more than about 2%, e.g., not more than about 1%, not more than about 0.6%, or not more than about 0.5% by weight of phenoxyethanol, based on the total weight of the preparation.
• a preparation it is advantageous for a preparation to contain at least about 0.0001%, e.g., at least about 0.001%, at least about 0.005%, or at least about 0.01%, but not more than about 5%, e.g., not more than about 1%, or not more than about 0.5% by weight of licochalcone A, based on the total weight of the preparation.
• the preparation it is further advantageous for the preparation to contain from about 0.001% to about 20% by weight, e.g., from about 0.01% to about 10% by weight, from about 0.05% to about 5% by weight, or from about 0.1% to about 5% by weight of one or more polyols, based on the total weight of the preparation.
• Non-limiting examples of polyols which are suitable for the purposes of the invention include glycerin, butylene glycol, dipropylene glycol, propylene glycol, pentanediol, and hexanediol.
• preparations according to the present invention may furthermore be advantageous for the preparations according to the present invention to contain licochalcone in the form of a constituent of a plant extract, in particular of an extract of radix glycyrrhizae inflatae.
• the cosmetic or dermatological preparations according to the invention may contain from about 0.0001% to about 10% by weight, in particular from about 0.005% to about 5% by weight, very particularly from about 0.01% to about 1% by weight of an extract of radix glycyrrhizae inflatae , based on the total weight of the preparation.
• licochalcone A in other vehicle systems, e.g., in a concentration of from about 0.0001% to about 5% by weight, in particular from about 0.001% to about 1% by weight, very particularly from about 0.003% to about 0.05% by weight.
• (A:B:C) is selected as a:b:c, where a, b, and c represent independently of one another positive rational numbers of from about 0.001 to about 200, preferably from about 0.001 to about 10, and A, B and C represent licochalcone A, phenoxyethanol and glycerin, respectively.
• the active substance combinations according to the present invention are used in cosmetic or dermatological compositions in concentrations of preferably at least about 0.0005%, e.g., at least about 0.01% and preferably not more than about to about 50%, e.g., not more than about 20% by weight, based on the total weight of the preparation.
• active substance combinations according to the invention for the prophylaxis and treatment of inflammatory skin conditions—including atopic eczema—and/or for the protection of the skin in the case of dry skin determined to be sensitive is also within the scope of the present invention.
• active substance combinations according to the invention for the production of cosmetic or dermatological preparations for the treatment and/or prophylaxis of pigmentation disorders is also within the scope of the present invention.
• active substance combinations according to the invention for the production of cosmetic or dermatological preparations for the treatment and/or prophylaxis of the symptoms of intrinsic and/or extrinsic skin aging and for the treatment and/or prophylaxis of the harmful effects of ultraviolet radiation on the skin is also within the scope of the present invention.
• Cosmetic or dermatological preparations according to the invention preferably contain from about 0.0001% to about 10% by weight, particularly preferably from about 0.001% to about 1% by weight, of active substance combination according to the present invention, based on the total weight of the preparations.
• active substance combinations or cosmetic or topical dermatological preparations with an effective content of active substance combinations according to the invention for the cosmetic or dermatological treatment and/or prophylaxis of undesirable skin conditions.
• antioxidants may be present in preparations which contain active substance combinations according to the invention.
• the antioxidants may advantageously be chosen from amino acids (for example glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles (for example urocanic acid) and derivatives thereof, peptides, such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (for example anserine), carotenoids, carotenes (for example ⁇ -carotene, ⁇ -carotene, lycopene) and derivatives thereof, lipoic acid and derivatives thereof (for example, dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (for example, thioredoxin, glutathione, cysteine, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl,
• the amount of the antioxidants (one or more compounds) in the preparations is preferably from about 0.001% to about 30% by weight, e.g., from about 0.05% to about 10% by weight, in particular from about 0.1% to about 5% by weight, based on the total weight of the preparations.
• the prophylaxis or the cosmetic or dermatological treatment with the active substance combination according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active substance combination according to the invention takes place in the customary manner, such that the active substance combination according to the invention or the cosmetic or topical dermatological preparations with an effective content of the active substance combination according to the invention is applied to the affected areas of the skin.
• the active substance combination according to the invention can be advantageously incorporated into customary cosmetic and dermatological preparations which can be present in various forms.
• they can, for example, be present in the form of a solution, an emulsion of the water-in-oil (W/O) type or of the oil-in-water (O/W) type, or in the form of a multiple emulsion, for example of the water-in-oil-in-water (W/O/W) type, or the oil-in-water-in-oil (O/W/O) type, as a hydrodispersion or lipodispersion, a gel, a solid stick, or also as an aerosol.
• emulsions e.g., in the form of a cream, a lotion, a foam, a cosmetic milk
• emulsions are advantageous and contain, for example, fats, oils, waxes and/or other fatty substances, and also water and one or more emulsifiers, as is customarily used for this type of formulation.
• the cosmetic preparations according to the invention may therefore contain cosmetic auxiliaries as are customarily used in such preparations, e.g., preservatives, bactericides, deodorants, antiperspirants, insect repellants, vitamins, antifoams, dyes, coloring pigments, thickeners, emollients, moisturizers and/or humectants, fats, oils, waxes and/or other customary constituents of a cosmetic preparation, such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents and silicone derivatives.
• cosmetic auxiliaries as are customarily used in such preparations, e.g., preservatives, bactericides, deodorants, antiperspirants, insect repellants, vitamins, antifoams, dyes, coloring pigments, thickeners, emollients, moisturizers and/or humectants, fats, oils, waxes and/or other customary constituents of a cosmetic preparation
• Medicinal topical compositions for the purposes of the present invention generally comprise one or more medicaments in an effective concentration.
• Medicinal topical compositions for the purposes of the present invention generally comprise one or more medicaments in an effective concentration.
• Preparations according to the invention can advantageously also contain substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, from about 0.1% by weight to about 30% by weight, preferably from about 0.5% to about 10% by weight, in particular from about 1.0% to 6.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also be used as sunscreen for the hair.
• UVA filter substances for the purposes of the present invention include dibenzoylmethane derivatives, in particular 4-(tert-butyl)-4′-methoxydibenzoylmethane (CAS No. 70356-09-1), which is sold by Givaudan under the trademark Parsol® 1789 and by Merck under the trademark Eusolex® 9020.
• dibenzoylmethane derivatives in particular 4-(tert-butyl)-4′-methoxydibenzoylmethane (CAS No. 70356-09-1), which is sold by Givaudan under the trademark Parsol® 1789 and by Merck under the trademark Eusolex® 9020.
• Non-limiting examples of further advantageous UVA filter substances include hydroxybenzophenones which are characterized by the following structural formula: where
• a particularly advantageous hydroxybenzophenone for the purposes of the present invention is hexyl 2-(4′-diethylamino-2′-hydroxybenzoyl)benzoate (also: aminobenzophenone), which is characterized by the following structure: and is available under the trade name Uvinul A Plus from BASF.
• the total amount of one or more hydroxybenzophenones in the finished cosmetic or dermatological preparations is advantageously selected from the range of from about 0.01% by weight to about 20% by weight, preferably from about 0.1% to about 10% by weight, each based on the total weight of the preparations.
• Non-limiting examples of advantageous further UV filter substances in the context of the present invention include sulfonated, water-soluble UV filters, such as, e.g.,
• Advantageous UV filter substances in the context of the present invention are furthermore so-called broad-band filters, i.e., filter substances which absorb both UVA and UVB radiation.
• Advantageous broad-band filters or UVB filter substances include, for example, triazine derivatives, such as e.g.
• Another advantageous broad-band filter for the purposes of the present invention is 2,2′-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)-phenol) which is available under the trade name Tinosorb® M from CIBA-Chemikalien GmbH.
• Another advantageous broadband filter for the purposes of the present invention is 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-[(tri-methylsilyl)oxy]-disiloxanyl]propyl]-phenol (CAS No.: 155633-54-8) with the INCI name drometrizole trisiloxane, which is available under the trade name Mexoryl® XL from Chimex.
• the further UV filter substances may be oil-soluble or water-soluble.
• Advantageous oil-soluble UVB and/or broad-band filter substances for the purposes of the present invention include, e.g.:
• Advantageous water-soluble filter substances include, e.g., sulfonic acid derivatives of 3-benzylidenecamphor, such as, e.g., 4-(2-oxo-3-bornylidenemethyl)benzenesulfonic acid, 2-methyl-5-(2-oxo-3-bornylidenmethyl)-sulfonic acid and salts thereof.
• sulfonic acid derivatives of 3-benzylidenecamphor such as, e.g., 4-(2-oxo-3-bornylidenemethyl)benzenesulfonic acid, 2-methyl-5-(2-oxo-3-bornylidenmethyl)-sulfonic acid and salts thereof.
• a further light-protection filter substance which may advantageously be used according to the invention is ethylhexyl-2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul®. N 539.
• Particularly advantageous preparations for the purposes of the present invention which are characterized by a high or very high UVA and/or UVB protection furthermore preferably comprise, in addition to the filter substance(s) according to the invention, further UVA and/or broad-band filters, in particular dibenzoylmethane derivatives [for example, 4-(tert-butyl)-4′-methoxydibenzoylmethane], phenylene-1,4-bis-(2-benzimidazyl)-3,3′-5,5′-tetrasulfonic acid and salts thereof, 1,4-di(2-oxo-10-sulfo-3-bornylidenemethyl)-benzene and/or salts thereof and/or 2,4-bis- ⁇ [4-(2-ethylhexyloxy)-2-hydroxy]-phenyl ⁇ -6-(4-methoxyphenyl)-1,3,5-triazine, in each case individually or in any desired combinations with one another.
• UV filters which can be employed for the purposes of the present invention is of course not intended to be limiting.
• the preparations according to the invention may advantageously comprise the substances which absorb UV radiation in the UVA and/or UVB range in a total amount of, e.g., from about 0.1% by weight to about 30% by weight, preferably from about 0.5% to about 20% by weight, in particular from about 1.0% to about 15.0% by weight, in each case based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also be used as sunscreens for the hair.
• Cosmetic and dermatological preparations according to the invention may advantageously also contain inorganic pigments based on metal oxides and/or other metal compounds which are poorly soluble or insoluble in water, in particular oxides of titanium (TiO 2 ), zinc (ZnO), iron (e.g., Fe 2 O 3 ), zirconium (ZrO 2 ), silicon (SiO 2 ), manganese (e.g., MnO), aluminum (Al 2 O 3 ), cerium (e.g., Ce 2 O 3 ), mixed oxides of the corresponding metals and mixtures of such oxides.
• Particularly preferred pigments include those based on TiO 2 .
• the inorganic pigments it is particularly advantageous, although not mandatory, for the inorganic pigments to be present in hydrophobic form, i.e., to have been treated on the surface to become water-repellent.
• This surface treatment may involve providing the pigments with a thin hydrophobic layer by processes known per se.
• One such process involves, for example, producing the hydrophobic surface layer in accordance with a reaction according to n TiO 2 +m(RO) 3 Si—R′—>n TiO 2 (surf.)
• n and m are desired stoichiometric parameters
• R and R′ are the desired organic radicals.
• hydrophobicized pigments prepared in accordance with DE-OS 33 14 742, the entire disclosure whereof is incorporated by reference herein, are advantageous.
• Advantageous TiO 2 pigments are also available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.
• the preparations may also contain anionic, nonionic, and/or amphoteric surfactants.
• Surfactants are amphophilic substances which are capable of dissolving organic, nonpolar substances in water.
• hydrophilic moieties of a surfactant molecule are in most cases polar functional groups, for example —COO ⁇ , —OSO 3 ⁇ , —SO 3 ⁇ , whereas the hydrophobic parts normally represent nonpolar hydrocarbon residues.
• surfactants are classified according to the type and charge of the hydrophilic portion of the molecule. In this regard, it is possible to distinguish between four groups:
• Anionic surfactants normally comprise carboxylate, sulfate, or sulfonate groups as functional groups. In an aqueous solution, they form negatively charged, organic ions in an acidic or neutral environment. Cationic surfactants are characterized nearly exclusively by the presence of quaternary ammonium groups. In an aqueous solution, they form positively charged, organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups, and accordingly in an aqueous solution act as anionic or cationic surfactants depending on the pH value. In a strongly acidic environment, they exhibit a positive charge, and in an alkaline environment they exhibit a negative charge. In the neutral pH range, however, they are zwitterionic, as demonstrated by the following example:
• Nonionic surfactants are polyether chains. Nonionic surfactants do not form ions in an aqueous medium.
• anionic surfactants that may advantageously be used for the purposes of the present invention include Acylamino acids (and salts thereof), such as:
• Quaternary surfactants contain at least one nitrogen atom, which is covalently bonded to 4 alkyl or aryl groups. Irrespective of the pH value, this results in a positive charge.
• Advantageous are alkylbetaine, alkylamidopropylbetaine, and alkylamidopropyl-hydroxysulfaine.
• the cationic surfactants that may be used in accordance with the invention can also be selected from quaternary ammonium compounds, in particular benzyltrialkyl ammoniumchlorides or bromides, such as, for example, benzyldimethylstearyl ammonium chloride, furthermore alkyltrialkyl ammonium salts, for example, cetyltrimethyl ammonium chloride or bromide, alkyldimethylhydroxyethyl ammonium chloride or bromide, dialkyldimethyl ammonium chloride or bromide, alkylamide ethyltrimethylammonium ether sulfates, alkylpyridinium salts, for example, lauryl or cetyl pyrimidinium chloride, imidazoline derivatives and compounds having cationic character, such as amine oxides, for example, alkyldimethylamine oxides or alkylaminoethyl dimethylamine oxides.
• anionic and/or amphoteric surfactants may also be advantageous to use a combination of anionic and/or amphoteric surfactants with one or more nonionic surfactants.
• the surface-active substance may, for example, be present in a concentration of from about 1% to about 95% by weight, based on the total weight of the preparations.
• the oil phase of the emulsions of the present invention may further be selected from esters of saturated and/or unsaturated, branched and/or unbranched alkane carboxylic acids having a chain length of from 3 to about 30 carbon atoms and saturated and/or unsaturated, branched and/or unbranched alcohols having a chain length of from 3 to about 30 carbon atoms; from esters of aromatic carboxylic acids and saturated and/or unsaturated, branched and/or unbranched alcohols having a chain length of from 3 to about 30 carbon atoms.
• ester oils may advantageously be selected from isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate, as well as synthetic, semisynthetic, and natural mixtures of such esters, for example, jojoba oil.
• the oil phase may advantageously be selected from branched and unbranched hydrocarbons and hydrocarbon waxes, silicone oils, dialkyl ethers, saturated and/or unsaturated, branched and/or unbranched alcohols, as well as fatty acid triglycerides, namely the triglycerol esters of saturated and/or unsaturated, branched and/or unbranched alkane carboxylic acids having a chain length of from about 8 to about 24, in particular from about 12 to about 18 carbon atoms.
• the fatty acid triglycerides may advantageously be selected, for example, from synthetic, semisynthetic and natural oils, for example, olive oil, sunflower seed oil, soy oil, peanut oil, rape oil, almond oil, palm oil, coconut oil, palm kernel oil, and the like.
• waxes for example, cetyl palmitate, as the only lipid component of the oil phase.
• the oil phase may also be selected from 2-ethylhexyl stearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 -alkyl benzoate, triglycerides of caprylic/capric acid, dicaprylyl ether and dicaprylyl carbonate.
• Particularly advantageous are mixtures of C 12-15 alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 12-15 alkyl benzoate and isotridecyl isononanoate, as well as mixtures of C 12-15 alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
• Non-limiting examples of hydrocarbons that may advantageously be used for the purposes of the invention include paraffin oil, squalane and squalene.
• the oil phase may advantageously also contain cyclic and/or linear silicone oils, or be composed entirely of such oils, although it is preferable to use an additional content of other oil phase components apart from the silicone oil(s).
• Such silicones or silicone oils may be in the form of monomers, which are generally characterized by the following structural elements:
• Linear silicones having two or more siloxyl units which may be used advantageously according to the present invention, are generally characterized by the following structural elements: where the silicon atoms can be substituted with identical or different alkyl radicals and/or aryl radicals, which are shown here in general terms by the radicals R 1 -R 4 (that is to say the number of different radicals is not necessarily limited to up to 4). m will usually assume values of from about 2 to about 200,000.
• Cyclic silicones which may be used advantageously according to the invention are generally characterized by the following structural elements: where the silicon atoms can be substituted with identical or different alkyl radicals and/or aryl radicals, which are shown here in general terms by the radicals R 1 -R 4 (that is to say the number of different radicals is not necessarily limited to up to 4). n will usually assume values of from 3/2 to about 20. Fractions for n take into consideration the fact that uneven numbers of siloxyl groups may be present in the ring.
• cyclomethicone e.g., decamethylcyclopentasiloxane
• silicone oils can also be used advantageously for the purposes of the present invention, for example, undecamethylcyclotrisiloxane, polydimethylsiloxane, poly(methylphenylsiloxane), cetyldimethicone, and behenoxydimethicone.
• mixtures of cyclomethicone and isotridecyl isononanoate and mixtures of cyclomethicone and 2-ethylhexyl isostearate.
• silicone oils of similar constitution to the above-described compounds whose organic side chains are derivatized, for example, polyethoxylated and/or polypropoxylated.
• silicone oils include, for example, polysiloxane-polyalkyl-polyether copolymers, such as cetyl-dimethicone copolyol, and (cetyl-dimethicone copolyol (and) polyglyceryl-4-isostearate (and) hexyl laurate).
• mixtures of cyclomethicone and isotridecyl isononanoate, and of cyclomethicone and 2-ethylhexyl isostearate are particularly advantageous.
• the aqueous phase of the preparations according to the invention may optionally comprise alcohols, diols or polyols of low carbon number, and ethers thereof, preferably ethanol, isopropanol, propylene glycol, glycerin, ethylhexylglycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products, and also, in particular, one or more thickeners which can advantageously be chosen from silicon dioxide and aluminum silicates.
• alcohols, diols or polyols of low carbon number, and ethers thereof preferably ethanol, isopropanol, propylene glycol, glycerin, ethylhexylglycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propy
• Preparations according to the invention which are present in the form of emulsions may advantageously comprise, in particular, one or more hydrocolloids.
• hydrocolloids may advantageously be chosen from gums, polysaccharides, cellulose derivatives, phyllosilicates, polyacrylates and/or other polymers.
• Preparations according to the invention which are present in the form of hydrogels may contain one or more hydrocolloids. These hydorcolloids may advantageously be selected, for example, from the above-mentioned group of thickeners.
• the gums include saps from plants or trees which harden in the air and form resins, and extracts from aquatic plants. From this group, gum arabic, carob flour, tragacanth, karaya, guar gum, pectin, gellan gum, carrageen, agar, algins, chondrus, xanthan gum may, for example, be chosen advantageously for the purposes of the present invention.
• derivatized gums such as, for example, hydroxypropyl guar (Jaguar® HP 8).
• Non-limiting examples of suitable polysaccharides and polysaccharide derivatives include hyaluronic acid, chitin and chitosan, chondroitin sulfates, starch and starch derivatives.
• Suitable cellulose derivatives include, for example, methylcellulose, carboxymethylcellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose.
• the phyllosilicates include naturally occurring and synthetic clays, such as, for example, montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates such as Veegum®. These can be used as such or in modified form, such as, for example, stearylalkonium hectorites.
• silica gels can also be used advantageously for the purposes of the present invention.
• the polyacrylates include, for example, Carbopol grades from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).
• the polymers include, for example, polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP/VA copolymers, polyglycols, and ammoniumpolyacryloyldimethyltaurates and ammoniumacryloyldimethyltaurate/-vinylpyrrolidone copolymers.
• Preparations according to the invention in the form of emulsions may comprise one or more emulsifiers.
• emulsifiers may advantageously be chosen from nonionic, anionic, cationic and amphoteric emulsifiers.
• Non-limiting examples of nonionic emulsifiers include
• Non-limiting examples of anionic emulsifiers include
• Non-limiting examples of cationic emulsifiers include
• Non-limiting examples of amphoteric emulsifiers include
• emulsifiers which include beeswax, wool wax, lecithin and sterols.
• Non-limiting examples of advantageous O/W emulsifiers include polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, for example:
• the O/W emulsifiers comprise saturated radicals R and R′ it is particularly advantageous to select the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O/W emulsifiers from substances with HLB values of from about 11 to about 18, e.g., from about 14.5 to about 15.5. If the O/W emulsifiers comprise unsaturated radicals R and/or R′, or if isoalkyl derivatives are present, the preferred HLB values of such emulsifiers can also be lower or higher than the indicated values.
• fatty alcohol ethoxylates from ethoxylated stearyl alcohols, cetyl alcohols and cetyl stearyl alcohols (cetearyl alcohols).
• Especially preferred fatty alcohol ethoxylates include:
• Sodium laureth-11-carboxylate may advantageously be used as an ethoxylated alkyl ether carboxylic acid salt.
• Sodium laureth 1-4 sulfate may advantageously be used as an alkyl ether sulfate.
• Polyethylene glycol(30)cholesteryl ether may advantageously be used as an ethoxylated cholesterol derivative.
• Polyethylene glycol(25)soyasterol has also proven advantageous.
• Polyethylene glycol(60) evening primrose glycerides may advantageously be used as ethoxylated triglycerides.
• fatty acid esters of polyethylene glycol glycerol from polyethylene glycol(20)glyceryl laurate, polyethylene glycol(21)glyceryl laurate, polyethylene glycol(22)glyceryl laurate, polyethylene glycol(23)glyceryl laurate, polyethylene glycol(6)glyceryl caprate/caprinate, polyethylene glycol(20)glyceryl oleate, polyethylene glycol(20)glyceryl isostearate, and polyethylene glycol(18)glyceryl oleate/cocoate.
• sorbitan esters from polyethylene glycol(20)sorbitan monolaurate, polyethylene glycol(20)sorbitan monostearate, polyethylene glycol(20)sorbitan monoisostearate, polyethylene glycol(20)sorbitan monopalmitate, and polyethylene glycol(20)sorbitan monooleate.
• W/O emulsifiers fatty alcohols having from about 8 to about 30 carbon atoms, monoglycerol esters of saturated and/or unsaturated, branched and/or unbranched alkanecarboxylic acids having a chain length of from about 8 to about 24, in particular from about 12 to about 18 carbon atoms, diglycerol esters of saturated and/or unsaturated, branched and/or unbranched alkane-carboxylic acids having a chain length of from about 8 to about 24, in particular from about 12 to about 18 carbon atoms, monoglycerol ethers of saturated and/or unsaturated, branched and/or unbranched alcohols having a chain length of from about 8 to about 24, in particular from about 12 to about 18 carbon atoms, diglycerol ethers of saturated and/or unsaturated, branched and/or unbranched alcohols having a chain length of from about 8 to about 24, in particular from about 12 to about 18 carbon atoms, diglycerol ethers of
• Non-limiting examples of particularly advantageous W/O emulsifiers include glyceryl monostearate, glyceryl monoisostearate, glyceryl monomyristate, glyceryl monooleate, diglyceryl monostearate, diglyceryl monoisostearate, propylene glycol monostearate, propylene glycol monoisostearate, propylene glycol monocaprylate, propylene glycol monolaurate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monocaprylate, sorbitan monoisooleate, sucrose distearate, cetyl alcohol, stearyl alcohol, arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol(2)stearyl ether (steareth-2), glyceryl monolaurate, glyceryl monocaprinate, glyceryl monocaprylate
• EXAMPLE 1 O/W Night Cream % by weight Glyceryl stearate citrate 2 Shea butter 2 Stearyl alcohol 2 Cetyl alcohol 2 Hydrogenated coco glycerides 2 Caprylic acid/capric acid triglyceride 2 Ethylhexyl cocoate ester 2 Cyclomethicone 3 Dicaprylyl ether 2 Tocopherylacetate 1 Sodium ascorbylphosphate 0.1 Licochalcone A 0.01 Retinyl palmitate 0.1 Phenoxyethanol 0.6 p-Hydroxybenzoic acid alkyl ester (paraben) 0.6 Ethylhexylglycerin 0.5 Polyacrylic acid (Carbomer) 0.1 EDTA 0.2 Glycerin 10 Water-soluble and/or oil-soluble dyes 0.05 Fillers/additives (SiO 2 , BHT) 0.2 Perfume q.s. Water ad 100
• EXAMPLE 2 Cream % by weight Glyceryl stearate, self-emulsifying 5 Stearyl alcohol 1 Shea butter 1 C 12-15 Alkyl benzoate 3 Caprylic acid/capric acid triglycerides 2 Mineral oil 1 Dicaprylyl carbonate 3 Ethylhexyl cyanodiphenylacrylate (octocrylene) 5 Ethylhexyl triazone 1 Bis-ethylhexyloxyphenol-methoxyphenyl triazine 1 Citric acid, sodium salt 0.1 Licochalcone A 0.05 Phenoxyethanol 0.6 p-Hydroxybenzoic acid alkyl ester (paraben) 0.3 Hexamidine diisethionate 0.04 1,3-Dimethylol-5,5-dimethyl-hydantoin(DMDM hydantoin) 0.1 EDTA 0.2 Ethanol (denaturated) 2 Ammoniumacryloyldimethyltaurate/vin
• EXAMPLE 4 Cream % by weight Glyceryl stearate 1 Stearic acid 3 Stearyl alcohol 2 Cetyl alcohol 2 C 12-15 Alkyl benzoate 2 Caprylic acid/capric acid triglycerides 2 Macadamia oil 1 Myristy lmyristates 2 Dimethicone 2 Hydrogenated coco glycerides 1 Ethylhexylglycerin 0.5 Tocopheryl acetate 1 Licochalcone A 0.01 Creatine 0.1 Ubiquinone (Q10) 0.03 Phenoxyethanol 0.4 p-Hydroxybenzoic acid alkyl ester (paraben) 0.3 Iodopropynylbutylcarbamate 0.02 Cyclodextrin 0.3 Iminodisuccinate 0.2 Carbomer 0.3 Glycerin 5 Butylene glycol 1 Methylpropanediol 1 Additives (SiO 2 , talc) 0.5 Perfume q
• EXAMPLE 7 O/W Cream % by weight Glyceryl stearate 2.5 PEG-40-stearate 1 Cetearyl alcohol 2 Hydrogenated coco glycerides 1 Myristyl myristate 2 C 12-15 Alkyl benzoate 4 Caprylic acid/capric acid triglycerides 2 Octyldodecanol 1 Dicaprylyl carbonate 3 Ethylhexyl cyanodiphenylacrylate (octocrylene) 5 2-Hydroxy-4-methoxy-benzophenone (oxybenzone) 3 Ubiquinone (Q10) 0.03 Licochalcone A 0.005 alpha-Glucosylrutin 0.1 Ceramide III 0.1 Phenoxyethanol 0.5 p-Hydroxybenzoic acid alkyl ester (paraben) 0.4 Iodopropynylbutylcarbamate 0.05 2-Ethylhexylglycerin 0.5 Polyacrylic acid (Carbomer)
• EXAMPLE 8 O/W cream % by weight Polyglyceryl-3-methylglucose distearate 3 Cetyl alcohol 3 C 12-15 Alkyl benzoate 2 Butylene glycol dicaprylate/dicaprate 2 Caprylic acid/capric acid triglycerides 2 Hydrogenated polydecene 1 Dimethylpolysiloxane (dimethicone) 1 Isodecyl neopentanoate 4 Bis-ethylhexyloxyphenol-methoxyphenyltriazine 1 Ethylhexyl methoxycinnamate 5 Licochalcone A 0.005 Sodium ascorbylphosphate 0.1 EDTA 0.2 Phenoxyethanol 0.4 Iodopropynylbutylcarbamate 0.05 p-Hydroxybenzoic acid alkyl ester (paraben) 0.4 Ethanol denaturated 2 Carbomer 0.2 Glycerin 5 Additives (distarch
• EXAMPLE 9 O/W Cream % by weight Cetearyl glucoside 2 Myristyl myristate 1 Stearyl alcohol 4 C 12-15 Alkyl benzoate 2 Caprylic acid/capric acid triglycerides 3 Hydrogenated polydecene 1 Dicaprylyl carbonate 3 Polydecene 4 Ethylhexyl methoxycinnamate 3 Ethylhexyl cyanodiphenylacrylate (octocrylene) 3 Butyl methoxydibenzoylmethane 2 Licochalcone A 0.01 Ubiquinone (Q10) 0.1 Tocopheryl acetate 1 Trisodium EDTA 0.1 Phenoxyethanol 0.7 p-Hydroxybenzoic acid alkyl ester (paraben) 0.4 Ethylhexylglycerin 0.4 Xanthan gum 0.1 Carrageenan 0.1 Aluminum starch octenylsuccinates 1 Glycerin
• EXAMPLE 10 W/O Cream % by weight Polyglyceryl-3-diisostearate 5.0 Polyglyceryl-2-dipolyhydroxystearate 2.5 Cetearyl alcohol 2 Cetyl alcohol 2 C 12-15 Alkyl benzoate 8 Caprylic acid/capric acid triglycerides 6 Octyldodecanol 5 Octamethyltetrasiloxane (cyclomethicone) 2 Lactic acid 5 Citric acid sodium salt 0.5 Butyl methoxydibenzoylmethane 1 Ethylhexyl triazone 1 Ethylhexyl methoxycinnamate 5 Licochalcone A 0.001 Campesterol 0.01 Retinyl palmitate 0.05 Phenoxyethanol 0.4 p-Hydroxybenzoic acid alkyl ester (paraben) 0.1 Glycerin 7 Fillers (EDTA, aluminum stearate, BHT) 0.6 Perfume q.s. Water ad 100
• EXAMPLE 11 Microemulsion % by weight Lecithin 1.8 PEG-50 hydrogenated castor oil isostearate 5.2 Dicaprylyl ether 7.0 Phenoxyethanol 0.5 p-Hydroxybenzoic acid alkyl ester (paraben) 0.1 Diazolidinylurea 0.2 2-Ethylhexylglycerin 0.5 Tricontayl PVP 0.3 Licochalcone A 0.01 ⁇ -Sitosterol 0.001 Glycerin 7 Butylene glycol 3 Additives (talc, BHT, EDTA) 0.5 Perfume q.s. Water ad 100
• EXAMPLE 12 Pickering Emulsion % by weight Microcrystalline wax 4.5 Carnauba wax 1.5 Candelilla wax 4.0 Lanolin oil 4.0 Bis-diglyceryl polyacyladipate-2 3.5 Dimethicone 1.0 Isopropyl palmitate 3.5 Triisostearin 3.0 Myristyl lactate 4.0 Jojoba oil 2.0 Hydrogenated polydecene 2.5 Octyldodecanol 2.5 Licochalcone A 0.01 Phenoxyethanol 0.3 Ethylhexyl methoxycinnamate 2 Butyl methoxydibenzoylmethane 0.5 Micronized titanium dioxide (Eusolex T 2000) 2.0 Titanium dioxide CI 77891 4.0 Iron oxide CI 77491, 77492, 77499 3.2 D&C Red 7 0.6 Tocopheryl acetate 1.0 Xylitol 2.0 EDTA 0.2 Glycerin 5.0 Preservatives, BHT, perfume, aroma q.s. Water 30.0 Castor oil
• EXAMPLE 13 W/O Care Stick % by weight Caprylic acid/capric acid triglycerides 8 Octyldodecanol 7 Paraffin oil 2 Pentaerythrityl tetraisostearate 2 C 12-45 Alkyl benzoate 2 Jojoba oil 2 PEG-45/dodecyl glycol copolymer 3 Polyglyceryl-3 diisostearate 2.5 Sucrose distearate 0.5 Bis-diglyceryl polyacyladipate-2 9 Cetyl palmitate 2.5 C 16-36 Alkyl stearates 14 Carnauba wax 1.5 Beeswax 0.5 Ethylhexyl cyanodiphenylacrylate (octocrylene) 2 Licochalcone A 0.01 Phenoxyethanol 0.2 Bismuth oxychloride (BiOCl) 2 PTFE 2.5 Pearlescent pigments 3 Rokonsal S1 0.4 Glycerin 5 Perfume, BHT, neutralizing agents q.s. Water
• EXAMPLE 14 W/O Concealer Stick % by weight Caprylic acid/capric acid triglycerides 5 Octyldodecanol 5 Pentaerythrityl tetraisostearate 4 Dimethicone 0.5 PEG-45/dodecyl glycol copolymer 3.5 Bis-diglyceryl polyacyladipate-2 2 C 16-36 Alkyl stearate 1 C 20-40 Alkyl stearate 8 Carnauba wax 1.5 PVP/eicosene copolymer 1 Micronized titanium dioxide 2 Octyl methoxycinnamate 2 Licochalcone A 0.02 Phenoxyethanol 0.4 ⁇ -Sitosterol 0.01 Nylon-12 3 Lauroyl lysine 0.5 PMMA 6 Titanium dioxide coated with Al 2 O 3 7 Iron oxides 4 Ultramarine 0.5 Germall II 0.25 Glycerin 2 Perfume, BHT, neutralizing agents q.s. Water ad 100
• EXAMPLE 15 W/O Foundation Stick % by weight Caprylic acid/capric acid triglycerides 5 Octyldodecanol 5 Dicaprylyl carbonate 3 Dicaprylyl ether 2 Dimethicone 0.5 PEG-45/dodecyl glycol copolymer 2 Polyglyceryl-3-diisostearate 1.5 C 16-36 Alkyl stearate 2 C 20-40 Alkyl stearate 8 Licochalcone A 0.002 Phenoxyethanol 0.3 ⁇ -Sitosterol 0.02 Bismuth oxychloride (BiOCl) 3 Polymethylsilsesquioxane (Tospearl) 0.5 PMMA 3 Titanium dioxide coated with Al 2 O 3 6 Iron oxides 4 Ultramarine 0.6 Glycerin 10 Perfume, BHT, neutralizing agents q.s. Water ad 100
• EXAMPLE 16 W/O Sunscreen Stick % by weight Caprylic acid/capric acid triglycerides 8 Octyldodecanol 8 Pentaerythrityl tetraisostearate 8 Jojoba oil 1 Polyglyceryl-3 diisostearate 2 PEG-30 di-polyhydroxystearate 2.5 C 16-36 Alkyl stearate 1 C 20-40 Alkyl stearate 9 PVP/eicosene copolymer 1 Butyl methoxydibenzoylmethane 1 Micronized titanium dioxide 4 Ethylhexyl cyanodiphenylacrylate (octocrylene) 3.6 Octyl methoxycinnamate 3.6 Licochalcone A 0.001 Phenoxyethanol 0.4 ⁇ -Sitosterol 0.02 Boron nitride 3 Polymethylsilsesquioxane (Tospearl) 1 Silica LDP 1 Glydant plus 0.3 Glycerin 5 Perfum

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Birds (AREA)
• Emergency Medicine (AREA)
• Engineering & Computer Science (AREA)
• Botany (AREA)
• Mycology (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Alternative & Traditional Medicine (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Medical Informatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Cosmetics (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=34485243

Family Applications (4)

Family Applications After (3)

Country Status (4)

Cited By (9)

Families Citing this family (10)

Citations (8)

Family Cites Families (19)

• 2003
  • 2003-12-02 DE DE10356164A patent/DE10356164A1/de not_active Ceased
• 2004
  • 2004-11-17 EP EP04027339A patent/EP1541164A1/de not_active Ceased
  • 2004-11-17 EP EP18176913.4A patent/EP3406243B1/de active Active
  • 2004-11-17 ES ES18176913T patent/ES2944633T3/es active Active
  • 2004-12-02 US US11/001,224 patent/US20050136139A1/en not_active Abandoned
• 2006
  • 2006-09-01 US US11/514,214 patent/US8969418B2/en active Active
• 2008
  • 2008-11-13 US US12/270,009 patent/US20090062402A1/en not_active Abandoned
• 2015
  • 2015-01-26 US US14/604,949 patent/US9693973B2/en active Active - Reinstated

Patent Citations (8)

Also Published As

Similar Documents

Legal Events